Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Gilead Inks $7.8 Billion Deal to Purchase Arcellx

Gilead Inks $7.8 Billion Deal to Purchase Arcellx

by | Feb 23, 2026 10:52 am | Biotechnology

On February 23, Gilead Sciences, Inc. announced that it has entered into a definitive agreement to acquire Arcellx, Inc. Under the terms of the agreement, Arcellx shareholders will receive $115 per share in cash at closing plus one contingent value right of $5 per share, representing an implied equity value of $7.8 billion payable at closing. Arcellx is a clinical-stage biotechnology company focused on delivering a new class of immunotherapies for patients with cancer and other incurable diseases. Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), is currently in a Phase 2 pivotal trial for patients with relapsed or refractory multiple myeloma. According to its most... Read More »
GSK’s Tesaro Acquires Alteogen’s ALT-B4 

GSK’s Tesaro Acquires Alteogen’s ALT-B4 

by | Jan 21, 2026 1:32 pm | Biotechnology

GSK announced on January 20 that its portfolio company, Tesaro, will acquire Alteogen’s novel hyaluronidase enzyme ALT-B4 for $20 million.  Alteogen developed ALT-B4 using its bespoke Hybrozyme technology, which the company notes was designed to boost the flexibility and stability of protein structures while preserving the enzyme’s original mechanism of action.  Tesaro is a biopharmaceutical company whose major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved for use in ovarian cancer. It is owned by GSK.  The original press release notes that Tesaro plans to use the tech to develop and potentially market... Read More »
GSK Acquires Rapt Therapeutics For $2.2 Billion 

GSK Acquires Rapt Therapeutics For $2.2 Billion 

by | Jan 20, 2026 2:25 pm | Biotechnology

In its first transaction of the year, GSK Plc, announced that it acquired Rapt Therapeutics, Inc. for $58 per share.  That price equates to an aggregate equity value of $2.2 billion, according to GSK, which added that the upfront investment net of cash acquired comes to $1.9 billion. Net of cash acquired, GSK’s estimated upfront investment is $1.9 billion.  Based in South San Francisco, California, RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients. It develops novel therapies that are designed to modulate the critical immune responses underlying these diseases. According to a... Read More »
Gilead Inks $7.8 Billion Deal to Purchase Arcellx

Sanofi Acquires Dynavax Technologies for $2.2 Billion

by | Dec 24, 2025 9:45 am | Biotechnology

Sanofi is rounding out 2025 with a multi-billion-dollar transaction. On December 24, the company announced that it entered into an agreement to acquire Dynavax Technologies Corporation, based in Emeryville, California. Under the terms of the agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. Dynavax Technologies is a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate (Z-1018). According to its most recent annual SEC filing, Dynavax reported approximately $277.2 million... Read More »
Gilead Inks $7.8 Billion Deal to Purchase Arcellx

Innova Therapeutics Advances Novel Cancer Treatment With Enci Therapeutics Deal

by | Nov 26, 2025 12:08 pm | Biotechnology

Innova Therapeutics has completed its purchase of South Carolina-based biotechnology company Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086. IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets and antagonizes the Secreted Frizzled-Related Protein 2 (SFRP2) pathway. SFRP2 is a protein expressed at high levels in many solid and hematological malignancies, and its expression is correlated with patient outcomes, including overall survival, making it an important therapeutic target. As an SFRP2 antagonist, IVT-8086 selectively blocks the non-canonical Wnt/Ca2+ signaling... Read More »
Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion 

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion 

by | Nov 17, 2025 3:21 pm | Biotechnology

Johnson & Johnson (J&J) announced on November 17 that it entered into an agreement to acquire Halda Therapeutics. The purchase price is $3.05 billion.   Founded by Yale scientist, Professor Craig Crews, Halda Therapeutics is a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity Targeting Chimera platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer. The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer.  J&J is one of the largest global healthcare and pharmaceutical companies with more than 130,000 employees worldwide. Its business lines include... Read More »